glofitamab,Obinutuzumab 
roche
['lymsm', 'glofitamab', 'lymphoma']
phase 2 data indicate promising responses are possible with fixed-duration glofitamab in patients with heavily pretreated, highly refractory large b-cell lymphoma. #lymsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.